Current Status of and Opinions on Heart Transplantation in China

Abstract

The purpose of this review is to provide a comprehensive update on recent advances in heart transplantation in China. Despite advances in pharmacologic and device treatment of chronic heart failure, long-term morbidity and mortality remain high, and many patients progress to endstage heart failure. Heart transplantation has become standard treatment for selected patients with end-stage heart failure, though challenges still exist. However, multiple advances over the past few years will improve the survival and quality-of-life of heart transplant recipients. This article elaborates on the specific characteristics of heart transplantation in China, the current issues, development trends, and related experiences with heart transplantation in Wuhan Union Hospital.

References

[1] HuSS, GaoRL, LiuLS, et al.. Summary of the 2018 Report on Cardiovascular Diseases in China. Chin Cir J, 2019, 34: 209-220

[2] van derM P, GagginHK, DecGW. ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll Cardiol, 2019, 73(21): 2756-2768

[3] HayesDJ, CherikhWS, ChambersDC, et al.. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant, 2019, 38(10): 1015-1027

[4] MehraMR, CanterCE, HannanMM, et al.. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant, 2016, 35(1): 1-23

[5] WangY, CaiJ, SunY e. al.. J Thorac Dis, 2018, 10(4): 2153-2165

[6] GuglinM, ZuckerMJ, BorlaugBA, et al.. Evaluation for Heart Transplantation and LVAD Implantation: JACC Council Perspectives. J Am Coll Cardiol, 2020, 75(12): 1471-1487

[7] KormosRL, CowgerJ, PaganiFD, et al.. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant, 2019, 38(2): 114-126

[8] RoseEA, GelijnsAC, MoskowitzAJ, et al.. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med, 2001, 345(20): 1435-1443

[9] MassadM G. Christiaan Neethling Barnard (1922- 2001). J Thorac Cardiovasc Surg, 2002, 123(1): 1-2

[10] IyerA, GaoL, DoyleA, et al.. Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors. Am J Transplant, 2015, 15(2): 371-380

[11] DhitalKK, IyerA, ConnellanM, et al.. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. Lancet, 2015, 385(9987): 2585-2591

[12] BoucekMM, MashburnC, DunnSM, et al.. Pediatric heart transplantation after declaration of cardiocirculatory death. N Engl J Med, 2008, 359(7): 709-714

[13] MesserS, PageA, AxellR, et al.. Outcome after heart transplantation from donation after circulatorydetermined death donors. J Heart Lung Transplant, 2017, 36(12): 1311-1318

[14] Pediatr Transplant, 2017, 21(8):

[15] ChewHC, IyerA, ConnellanM, et al.. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. J Am Coll Cardiol, 2019, 73(12): 1447-1459

[16] KransdorfEP, KittlesonMM, BenckLR, et al.. Predicted heart mass is the optimal metric for size match in heart transplantation. J Heart Lung Transplant, 2019, 38(2): 156-165

[17] HolzhauserL, ImamuraT, BassiN, et al.. Increasing heart transplant donor pool by liberalization of size matching. J Heart Lung Transplant, 2019, 38(11): 1197-1205

[18] WoolleyAE, SinghSK, GoldbergHJ, et al.. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med, 2019, 380(17): 1606-1617

[19] RadziY, ShezadM F, Danziger-IsakovL, et al.. Using hepatitis C and B virus-infected donor organs for pediatric heart transplantation. J Thorac Cardiovasc Surg, 2019, 158(2): 548-553

[20] CostanzoMR, DipchandA, StarlingR, et al.. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant, 2010, 29(8): 914-956

[21] YamaniMH, TaylorDO, RodriguezER, et al.. Transplant vasculopathy is associated with increased AlloMap gene expression score. J Heart Lung Transplant, 2007, 26(4): 403-406

[22] DeV I, ValantineHA, SnyderTM, et al.. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med, 2014, 6(241): 241ra77

[23] Wever-PinzonO, RomeroJ, KelesidisI, et al.. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol, 2014, 63(19): 1992-2004

[24] WangY, CaiJ, SunY, et al.. Extended donor criteria in heart transplantation: a retrospective study from a single Chinese institution. J Thorac Dis, 2018, 10(4): 2153-2165

[25] WuJ, ZhangH, ShiX, et al.. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction. Immunity, 2017, 47(6): 1114-1128

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology